AESTHETIC BLENDS
AOD / Tesamorelin
Co-formulated AOD-9604 and Tesamorelin research peptide blend. Investigated in lipolysis and GH-axis literature.
Bundle & save
Free shipping
on orders over $300
Damage protection
replacement guarantee
Secure checkout
3D Secure
Certificate of Analysis
Third-party tested · ISO/IEC 17025 accredited
—
purity
✓ Passed full QC panel
- Variant
- AOD / Tesamorelin · 5 mg / 5 mg
- Lot #
- —
- Labeled
- 5 mg / 5 mg
- Tested
- —
Full QC panel
- Purity (HPLC)
- —
- Net Peptide Content
- Pass
- Identity (HPLC-MS)
- Confirmed
- Heavy Metals (ICP-MS)
- Not detected
- Sterility
- No growth
- Endotoxin (LAL)
- Within limits
Purity, lot and tested date are per-lot; remaining QC rows are representative — exact values on the CoA.
Compound Information
Chemical and structural properties
Chemical identity verified via NIH PubChem · biological targets characterized from the peer-reviewed literature.
Molecular profile
Components
- AOD-9604
- CAS 221231-10-3C78H123N23O23S2
- Tesamorelin
- CAS 218949-48-5C221H366N72O67S
- Type
- Combination blend
Biological targets
Interactions
- Primary target
- Combination — see component compounds
- Pathway
- Lipolytic hGH-fragment signaling (AOD-9604) with GHRHR stimulation (Tesamorelin)
- Mechanism
- Co-formulated AOD-9604 and Tesamorelin research blend
- Research area
- Metabolic and growth-hormone axis research
Physical properties
Handling & Storage
- Appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in sterile or bacteriostatic water; reconstitute prior to use
- Storage
- 2-8 deg C, protect from light
- Country of origin
- USA
Sources & References
Peer-reviewed research
Indexed in NIH PubMed. Provided for research context; not a claim of clinical outcome.
INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS : JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
2001 · PMID 11673763
Heffernan MA et al.
View Source ↗AIDS (LONDON, ENGLAND)
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
2024 · PMID 38905488
Russo SC et al.
View Source ↗RECENT PATENTS ON ENDOCRINE, METABOLIC & IMMUNE DRUG DISCOVERY
Current updates in the medical management of obesity
2012 · PMID 22435392
Khan A et al.
View Source ↗THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
2010 · PMID 20554713
Falutz J et al.
View Source ↗HORMONE RESEARCH
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2000 · PMID 11146367
Ng FM et al.
View Source ↗
⚠ Important research notice
PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
All the research peptides you need, with the peace of mind at your fingertips.
Stay Connected with Aminologix
Be the first to receive exclusive discount codes, new product launches, special offers, educational content, research updates, and company news. No spam. Unsubscribe anytime.